SEATTLE--(BUSINESS WIRE)--June 28, 2006--Targeted Genetics Corporation (Nasdaq:TGEN - News) announced today that it has entered into a collaboration and license agreement with the International Aids Vaccine Initiative (IAVI), Columbus Children's Research Institute (CCRI) at Columbus Children's Hospital and The Children's Hospital of Philadelphia (CHOP) in support of the development and commercialization of HIV/AIDS vaccines. The new agreement addresses development and commercialization issues consistent with the significant progress made in the HIV/AIDS vaccine development program. The new agreement supersedes a previous collaboration agreement entered into by Targeted Genetics, IAVI and CCRI in 2000, when the parties started working together on the development of an HIV/AIDS vaccine for the developing world.
